JMP Securities analyst Liisa A. Bayko raised her price target on Sarepta Therapeutics to $275 after hosting a dinner with Sarepta management on the heels of the R&D day at which the company revealed its "landmark" gene therapy data, noting that the dinner meeting provided her with more color on the micro-dystrophin gene therapy development strategy and commercial plans for the DMD franchise. She keeps an Outperform rating on Sarepta and continues to recommend the shares as she sees potential for significant upside as the program becomes further derisked with additional data, such as at the World Muscle Society meeting in early October.